PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10232563-16	1999	In patients on NEO, the concentration of CsA 2 hr after dosing (C2) closely reflected AUC0-6 (r2 = 0.93), whereas there was a poorer correlation in patients on SIM (r2 = 0.73) CONCLUSIONS: Cmax and/or AUC0-6 may provide better markers than trough levels for monitoring CsA-based immune suppression after orthotopic liver transplantation.	Cyclosporine	15-18	IK cytokine	Homo sapiens	41-46	
10674906-2	2000	We report here 9 cases of neutropenic HLH, of which 8 were treated with cyclosporin (CSA, 2-6 mg/kg/day; continuous infusion, or 6 mg/kg/day; per os, for periods ranging from 9 days to >8 weeks) in the initial neutropenic phase during induction treatment using corticosteroids and etoposide.	Cyclosporine	72-83	IK cytokine	Homo sapiens	85-93	
12364628-2	2002	METHODS: Sixteen patients who were still active despite combination therapy with optimal doses of methotrexate (MTX 15-17.5 mg/week) and cyclosporin A (CsA 2.5-3.5 mg/day) received infliximab.	Cyclosporine	137-150	IK cytokine	Homo sapiens	152-157	
8939689-5	1996	Here we describe the synthesis of a novel CID, (CsA)2, that has two identical protein-binding surfaces derived from the immunosuppressant cyclosporin A (CsA).	Cyclosporine	138-151	IK cytokine	Homo sapiens	48-53	
8939689-7	1996	RESULTS: (CsA)2 was synthesized in six synthetic steps and 30% overall yield from cyclosporin.	Cyclosporine	82-93	IK cytokine	Homo sapiens	10-15